Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
If you begin treatment with lower muscle mass, you face greater vulnerability to functional losses
Served with crackers
Select at least 2 products to compare
Furthermore, in signaling studies that used cell lines with recombinantly expressed human GIPR or GLP-1R, tirzepatide stimulated cyclic adenosine monophosphate (cAMP) accumulation by either receptor with potency similar to that of native GIP and approximately 13-fold weaker than that of native GLP-1 [1]
doi: 10.1136/bmjnph-2022-000544 75
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
